Search filters

List of works by Ewa Janczewska

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

scientific article published on 4 May 2014

Acromegaly and the risk of cancer.

scientific article

Cardiovascular effects of growth hormone deficiency in adults

scientific article published on 01 July 2002

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

scientific article published on 07 February 2020

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

scientific article published on 13 December 2019

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

scientific article published on March 2016

Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study

scientific article published on 03 July 2018

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

scientific article

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study

scientific article published on 05 September 2019

Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C

scientific article

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

scientific article

Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.

scientific article published on 26 May 2017

Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials

scientific article published on 27 August 2015

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

scientific article published on 28 November 2016

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

scientific article published on 01 May 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

scientific article published on 13 January 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

scientific article published in September 2022

Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters

article

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

scientific article published in February 2018

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

scientific article published on 10 November 2020

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1

scientific article published on 14 March 2019

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

scientific article published on 13 June 2020

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

scientific article published on 13 January 2022

Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)

scientific article

Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)

scientific article published on 01 January 2011

Prevalence of HCV genotypes in Poland - the EpiTer study

scientific article published on 28 November 2016

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

scientific article published on 03 March 2019

Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study

scientific article published on 25 July 2019

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

scientific article published on 9 September 2016

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

scientific article

Recommendations for elastography-based imaging of liver.

scientific article

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

scientific article

Serum aminoterminal peptide of type III procollagen (PIIINP) and transforming growth factor-beta1 (TGF-beta1) levels in patients with chronic hepatitis B and C

scientific article published on 01 June 2003

Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin

scientific article published in January 2007

Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication

scientific article published in 2022

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

scientific article

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 4 June 2014

TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.

scientific article published in June 2005

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

scientific article published on 4 December 2013

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study

scientific article published on 6 January 2018

[Quantitative assessment of mRNA TGF-beta1 in liver tissue in connection with serum mean daily level of TGF-1 in chronic hepatitis B patient]

scientific article published on 01 August 2005

[Treatment of patients with chronic viral hepatitis type B and C]

scientific article published on 01 April 2003

sPECAM-1 and sVCAM-1: Role in Pathogenesis and Diagnosis of Chronic Hepatitis C and Association with Response to Antiviral Therapy.

scientific article published on March 2009

Paulina is supported by:

About Paulina

Help